Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

ADCT

ADCT News

Newswire

10:56

ADC Therapeutics Updates LOTIS-7 Trial Results for ZYNLONTA and Glofitamab in Relapsed or Refractory DLBCL

07:46

ADC Therapeutics shares surge 15.22% premarket on positive LOTIS-7 trial data showing 89.8% ORR and 77.6% CR rates in DLBCL patients.

07:33

ADC Therapeutics Reports 89.8% ORR, 77.6% CR for ZYNLONTA Combo.

16:15

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial and Share Updated Data on December 3, 2025

11:25

ADC Therapeutics Projects ZYNLONTA Peak Revenue Between $600M-$1B in the US, Highlights Expanded Clinical Milestones

View More

About ADCT

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More